Printer Friendly

CHERNE MEDICAL ANNOUNCES MAJOR IMPROVEMENTS IN FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS

 CHERNE MEDICAL ANNOUNCES MAJOR IMPROVEMENTS IN FOURTH QUARTER
 AND YEAR-END FINANCIAL RESULTS
 MINNEAPOLIS, March 26 /PRNewswire/ -- Cherne Medical, Inc. (NASDAQ: CHNE) reported a 58 percent decrease in loss for the year ending Dec. 31, 1991; $1,728,593 loss versus $4,122,656 loss, or $(.10) per share versus $(.23) per share for the same period a year ago. The results for the three month period ending Dec. 31, 1991, or $244,668 loss, or $(.01) per share versus $2,042,385 loss, or $(.12) per share for the same period last year represents a 88 percent reduction in loss.
 "I'm pleased that our expense control program has had such a positive impact on the fourth quarter and full year reporting periods. This was accomplished during a time when we had extremely limited financial resources and faced the challenge to expand clinical validation of the Variance Cardiograph," said David L. Printy, chairman, president and CEO. "With the strengthening of our financial resources following the January closing of our Private Equity Placement, we are now capable of an aggressive marketing program for the first time.
 "In addition to the positive trend of reported financial results, major accomplishments have taken place to advance the acceptance of the Variance Cardiograph in both Europe and the United States," said Printy. "This is evidenced by the publication of the Emergency Room application of our technology in the 20th Anniversary, January Edition of the Annals of Emergency Medicine. In Europe, the Variance Cardiograph and the outstanding work at the Karolinska Institut, Stockholm, Sweden was featured in the Swedish medical journal, Medicinsk Teknik.
 Cherne Medical, Inc. manufactures and markets the Variance Cardiograph, a resting, non-invasive, stress-free diagnostic instrument capable of identifying coronary artery disease even when no symptoms are present. The common stock of Cherne Medical, Inc. is traded on the national over-the-counter market under the NASDAQ symbol CHNE.
 CHERNE MEDICAL, INC.
 CONDENSED STATEMENT OF OPERATIONS
 Three Months Ended Year Ended
 12/31/91 12/31/90 12/31/91 12/31/90
 Revenues $6,597 $87,227 $73,650 $89,867
 Cost of sales
 and expenses 158,012 1,029,565 1,742,593 3,262,850
 Operating income
 (loss) (151,415) (942,338) (1,668,943) (3,172,983)
 Interest and misc.
 expenses (93,253) (1,100,047) (59,650) (949,673)
 Net income (loss) $(244,668) $(2,042,385) $(1,728,593) $(4,122,656)
 Net income (loss)
 per common share $(.01) $(.12) $(.10) $(.23)
 Weighted average
 shares 17,630,616 17,596,616 17,630,616 17,596,616
 NOTE: In the fourth quarter of 1990, the company recorded a one- time charge of $848,000 relating to a retirement agreement obligation between Lloyd G. Cherne and the company, as well as a $289,000 write- down in estimated current market value of real estate holdings awarded to the company in 1988 as part of a legal settlement. The retirement agreement was amended during 1991 and as a result the retirement liability was reversed and credited to common stock as a contribution to contributed capital during the third quarter of 1991.
 -0- 3/26/92
 /CONTACT: David L. Printy of Cherne Medical, 612-933-2838/
 (CHNE) CO: Cherne Medical, Inc. ST: Minnesota IN: MTC SU: ERN


AL -- MN006 -- 1927 03/26/92 11:40 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 26, 1992
Words:550
Previous Article:TEXACO ANNOUNCES OIL DISCOVERY, OFFSHORE PENINSULAR MALAYSIA
Next Article:THE HENLEY GROUP ANNOUNCES MERGER AGREEMENT
Topics:


Related Articles
CHERNE MEDICAL, INC. REDUCES THIRD QUARTER LOSS BY 25 PERCENT AND LOSS FOR NINE-MONTH PERIOD ENDED SEPT. 30, 1991 BY 33 PERCENT
CHERNE ANNOUNCES FIRST CLOSING OF ITS EQUITY PLACEMENT
CHERNE MEDICAL ANNOUNCES SALE OF TWO CHERNE VARIANCE CARDIOGRAPHS TO EAST COAST CARDIOLOGY CENTER
MAJOR IMPROVEMENT IN DIAGNOSIS OF HEART ATTACKS IN EMERGENCY DEPARTMENT USING CHERNE VARIANCE CARDIOGRAPH DOCUMENTED BY MINNEAPOLIS RESEARCH
CHERNE MEDICAL'S PRIVATE EQUITY PLACEMENT OVERSUBSCRIBED
CIRCON'S AUDITED 1991 NET INCOME UP 96 PERCENT
MAJOR REIMBURSEMENT RECEIVED FROM MEDICARE IN FLORIDA FOR CHERNE MEDICAL VARIANCE CARDIOGRAPH
CHERNE MEDICAL ANNOUNCES A 20 PERCENT REDUCTION IN OPERATING LOSS FOR THE FIRST QUARTER
CHERNE MEDICAL ANNOUNCES THE ESTABLISHMENT OF ITS FIRST NATIONAL DISTRIBUTOR NETWORK
CHERNE MEDICAL APPOINTS VICE CHAIRMAN, DEPARTMENT OF MEDICINE AT THE UNIVERSITY OF MASSACHUSETTS MEDICAL CENTER TO ITS MEDICAL ADVISORY BOARD

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters